1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,681 | 0,712 | 17.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| Do | Cereno Scientific - CS014 completes Phase I, path clears for Phase II | 190 | Edison Investment Research | Cereno Scientific has announced that its second clinical stage asset, CS014, has completed the Phase I safety study, with the conclusion of the second, multiple ascending dose (MAD) part of the trial... ► Artikel lesen | |
| Mi | CERENO SCIENTIFIC: Cereno completes CS014 trial ahead of June top-line data | 1 | Cision News | ||
| Mi | Cereno Scientific AB: Cereno Scientific reports that its Phase I trial of CS014 has been concluded and confirms that top-line results are anticipated in June 2025 | 34 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| Mo | Cereno Scientific to attend BIO International Convention 2025 - largest and most comprehensive event for biotechnology | 1 | Cision News | ||
| 17.03. | Cereno Scientific AB: Cereno Scientific extends patent protection for drug candidate CS1 in the US and has filed to extend market exclusivity to 2045 | 191 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 12.03. | Cereno Scientific secures FDA meeting to advance its development of CS1 for the treatment of rare disease PAH | 3 | Cision News | ||
| 28.02. | Cereno Scientific shares invitation to the webcast for the CS1 Phase IIa trial data presentation at 14:00 CET on March 4 | 1 | Cision News | ||
| 26.02. | CERENO SCIENTIFIC: Additional data strengthens Cereno's CS1 in PAH | 1 | Cision News | ||
| 25.02. | Cereno Scientific AB: Cereno Scientific publishes Year-end Report for 2024 (January 1 - December 31, 2024) | 89 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 25.02. | Cereno Scientific's lead candidate CS1's reverse vascular remodeling profile is accompanied by improvement of right-ventricular function in additional data from Phase IIa trial - webcast on March 4 | 1 | Cision News | ||
| 20.02. | Cereno Scientific to evaluate CS1 with advanced imaging technology | 1 | Cision News | ||
| 20.02. | Cereno Scientific submitted Type C meeting request with FDA for Phase II drug candidate CS1 in preparation for further clinical development | 1 | Cision News | ||
| 19.02. | Cereno Scientific received approval to initiate sub-study of the CS1 EAP using Fluidda's innovative imaging technology to obtain insights on the long-term disease-modifying potential of CS1 in PAH | 2 | Cision News | ||
| 14.02. | Cereno Scientific to attend BIO-Europe Spring 2025 - a leading partnering event for life science in Europe | 3 | Cision News | ||
| 13.02. | Cereno Scientific - CS014 achieves another Phase I milestone | 209 | Edison Investment Research | Cereno Scientific's second pipeline asset, CS014, continues to make steady progress through the clinic, with the company successfully completing the single ascending dose (SAD) part of the Phase I study... ► Artikel lesen | |
| 11.02. | Cereno Scientific's HDAC inhibitor CS014 advances | 1 | Cision News | ||
| 11.02. | Cereno Scientific's HDACi CS014 has successfully completed part one of its Phase I trial evaluating the safety profile with a single ascending dose (SAD) study | 1 | Cision News | ||
| 06.02. | Cereno Scientific to present at the 2025 Nordic-American Healthcare Conference, the most comprehensive Nordic life science innovation gathering in the US | 1 | Cision News | ||
| 27.12.24 | Cereno Scientific has enrolled 9 additional patients in its Expanded Access Program with CS1 providing more long-term safety and efficacy data in rare disease PAH | 2 | Cision News | ||
| 20.12.24 | Cereno Scientific announces that the registration of warrants and convertibles to Fenja and Arena has been completed and that delivery of the warrants has been initiated | 1 | Cision News |
Seite:
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,980 | -1,91 % | Qiagen NV-Aktie gewinnt 1,38 Prozent (35,71 €) | An der Börse notiert die Aktie von Qiagen NV aktuell etwas fester. Das Papier kostete zuletzt 35,71 Euro. Ein Kursplus von 1,38 Prozent steht gegenwärtig für die Qiagen NV-Aktie zu Buche. Das Wertpapier... ► Artikel lesen | |
| NUVALENT | 71,64 | 0,00 % | Nuvalent, Inc. - 8-K, Current Report | ||
| EVOTEC | 6,396 | +9,90 % | EQS-News: Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024 | EQS-News: Evotec SE
/ Schlagwort(e): Jahresbericht
Evotec SE stellt neue Strategie vor und gibt Ausblick für 2025 gestützt durch starkes Ergebnis im 4. Quartal 2024
17.04.2025... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,310 | 0,00 % | Why ADMA Biologics, Inc. (ADMA) Skyrocketed On Tuesday? | ||
| BEAM THERAPEUTICS | 17,000 | 0,00 % | Cathie Wood's ARK ETF focuses on Beam Therapeutics, Coinbase stock | ||
| TEMPUS AI | 40,450 | 0,00 % | Illumina, Tempus AI To Collaborate To Accelerate Genomic AI Innovation | SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) and Tempus AI, Inc. (TEM), Tuesday announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence... ► Artikel lesen | |
| ARVINAS | 8,600 | 0,00 % | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,620 | +0,04 % | Here's Why Summit Therapeutics Stock Soared 15% on Friday | ||
| BIONTECH | 85,55 | -1,67 % | BioNTech-Aktie: Das muss man wirklich wissen! | News von Trading-Treff.de BioNTech hat sich sehr stark in die neue Woche eingeklinkt. Das Unternehmen konnte ein Plus in Höhe von 2,6 % verzeichnen. Schon am Freitag war es an der US-Börse NASDAQ um... ► Artikel lesen | |
| 89BIO | 6,060 | 0,00 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 21,770 | +0,05 % | JMP maintains $87 target on Structure Therapeutics shares | ||
| RECURSION PHARMACEUTICALS | 5,485 | -0,27 % | Recursion lizenziert HealthVerity-Echtweltdaten für klinische Studien | ||
| ENLIVEN THERAPEUTICS | 16,530 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update | Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues
Expected monotherapy and combination data from the ELVN-002 Phase 1... ► Artikel lesen | |
| AMGEN | 243,65 | -0,06 % | Amgen-Aktie: Kurs fällt ab (237,5811 €) | Das Wertpapier von Amgen notiert heute ein wenig leichter. Die Aktie notiert derzeit bei 269,98 US-Dollar. Für die Amgen-Aktie steht gegenwärtig ein Abschlag von 4,48 Prozent zu Buche. Das Wertpapier... ► Artikel lesen | |
| BIOVENTUS | 7,820 | 0,00 % | Bioventus, Inc.: Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results | Accelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth quarter cash from operations of $19.3 million increased... ► Artikel lesen |
CERENO SCIENTIFIC AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,019 (+2,96 %) liegt der Kurs bei 0,661 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERENO SCIENTIFIC AB finden Sie auf Wallstreet Online.
